Washington University School of Medicine in St. Louis is radically advancing immunotherapy treatments and personalized cancer therapies. PICI researcher Robert D. Schreiber, PhD, has championed the power of immunotherapy for more than 25 years. He translates basic research principles into clinical trials and drives new therapeutic approaches. Matthew Gubin, PhD, Parker Bridge Scholar, works in Schreiber’s lab researching tumor growth and rejection to improve responses to checkpoint blockade therapies. Together with PICI, they focus on T-cells and activating responses for more patients and more cancer types. Robert D. Schreiber, PhD | Investigator Matthew Gubin, PhD | Bridge Scholar Related Research Project Tumor Neoantigen Selection Alliance (TESLA) Research Focus Tumor Antigen Discovery: Targeting Cancer Point of View PICI Catalyzes Scientific Innovation Cancer Research Heroes An Insider View of PICI’s Pancreatic Clinical Trial PRINCE Cancer Research Heroes PICI Takes On Prostate Cancer: A Q&A with the Experts Research Project TRIBUTE Cancer Research Heroes A Visionary Paving the Way for Faster and Better Cancer Cures Announcement Note from PICI’s President and CEO Jeff Bluestone: Introducing Our New Brand Clinical Trial The PORTER Trial